Background {#Sec1}
==========

Wound provides a warm, moist, and nutritive environment which is conducive to microbial colonization, proliferation, and infection. It can occur during trauma, accident, burn, surgical procedures or as a result of chronic disease conditions such as diabetes mellitus and leprosy \[[@CR1], [@CR2]\]. All wounds can be contaminated from endogenous sources of the patient (e.g. nasopharynx and gastrointestinal tract), the surrounding skin and/or the immediate environment. The local environment is particularly important for patients admitted in healthcare settings. Microbes in such wounds create a continuum from initial contamination all the way through colonization to fully blown infection. For this infection to occur, factors including the virulence characteristics of microbes, selection pressures, the host immune system, age and comorbid conditions of a patient play a critical role. Skin serves as a first line defense (innate immunity) in battle against microbes. Despite this, wound breaks the integrity of the skin, and creates an open filed for microbes thereby circumvents the innate immunity and establishes infection. It is crystal clear that wound infections have resulted in considerable morbidity, mortality, prolonged hospitalization and escalation of direct and indirect healthcare costs \[[@CR3], [@CR4]\].

Though it varies based on the wound source, the most commonly isolated gram-positive cocci are *Staphylococcus aureus* and *Coagulase Negative Staphylococci* (CoNS). Besides, gram-negative aerobic bacilli such as *Escherichia coli*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and *Proteus mirabilis* are the most prevailing clinically relevant isolates \[[@CR5]--[@CR9]\]. Among these isolates, *S. aureus* particularity Methicillin resistant strains (MRSA) as well as *P. aeruginosa* are typical biofilm producers making the wound infection difficult to treat using standard antibiotics \[[@CR3], [@CR10]--[@CR12]\].

Treatment of wound infections with antimicrobial agents as well as optimum treatment regimens remains ill defined. Many published guidelines are mainly based on expert opinion rather than evidence-based data. The selection of appropriate antimicrobial agents has been inconclusive. Though prophylactic use of antimicrobials can help reduce the risk of infection and promotes wound healing, it is not a direct substitute for good local wound care such as irrigation and surgical debridement. Moreover, judicious use of antimicrobials reduces the development of antimicrobial resistance (AMR) \[[@CR13]--[@CR15]\]. Review of recent practices has revealed that potentially inappropriate and inconsistent use of antimicrobials following surgical procedures contributes to development of AMR. In addition, appropriateness of the timing, the duration, route and selection of these agents remains elusive \[[@CR13], [@CR16]--[@CR18]\]. this systematic review and meta-analysis is aimed to provide nationwide pooled estimates of wound culture positivity, microbial profiles and AMR patterns of wound infection in Ethiopia. This will help as a benchmark for developing antimicrobial stewardship programs and generating evidence-based selection of antimicrobials thereby preserve the available antimicrobials and contain AMR.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

The identification and screening of studies as well as eligibility assessment of full texts was conducted in accordance with the preferred reporting items for systematic review and meta-analysis (PRISMA) statement \[[@CR19]\]. In addition, the content of this meta-analysis is well described in the completed PRISMA check list \[[@CR20]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The study protocol is registered on International Prospective Register of Systematic Reviews (PROSPERO) with reference number ID: CRD42019117638 and available online at: <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019117638>

Data sources and searching strategy {#Sec4}
-----------------------------------

Literature search was carried out through visiting electronic databases and indexing services. The PubMed, MEDLINE (Ovid®), EMBASE (Ovid®), CINAHL (EBSCOhost), and Google Scholar, were used as main source of data. Besides, other supplementary sources including ResearchGate, WorldCat, Science Direct and University repositories were searched to retrieve relevant data. Excluding the non-explanatory terms, the search strategy included important keywords and indexing terms: wound, wound infection (MeSH), "antimicrobial susceptibility", bacteria (MeSH), "antimicrobial resistance", "antibacterial resistance", and "Ethiopia". The MeSH terms, Boolean operators (AND, OR and NOT), and truncation were applied for appropriate searching and identification of records for the research question.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

### Inclusion criteria {#Sec6}

Studies conducted in EthiopiaStudies available online from 2000 to 2018Studies published in English languageLaboratory-based observational (e.g. cross-sectional) studies addressing the research question: studies dealing with wound culture positivity and prevalence of individual isolates recovered from wound samples as primary outcome measures

### Exclusion criteria {#Sec7}

Any review papers published in the study periodStudies having mixed sample sources (wound and non-wound samples concurrently. E.g. blood, urine, and other discharges)Wound samples taken from animalsIrretrievable full texts (after requesting full texts from the corresponding authors via email and/or Research Gate account)Studies with unrelated or insufficient outcome measuresStudies with outcomes of interest are missing or vague

Screening and eligibility of studies {#Sec8}
------------------------------------

Along with application of appropriate limits, online records from each database or directory were exported to ENDNOTE reference software version 8.2 (Thomson Reuters, Stamford, CT, USA). The records were then merged to one folder to identify and remove duplicates with the help of ENDNOTE and/or manual tracing as there is a possibility of several citation styles per study. Thereafter, two authors Mekonnen Sisay (MS) and Dumessa Edessa (DE) independently screened the title and abstracts with the predefined inclusion/exclusion criteria. Records which passed the screening phase were subjected for eligibility assessment of full texts. For this, two authors, MS and Teshager Worku (TW) independently collected full texts and evaluated their eligibility for meta-analysis. In each case, the third author was consulted to solve disagreement occurred between the two authors.

Data extraction {#Sec9}
---------------

Using standardized data abstraction format prepared in Microsoft Excel (Additional file [2](#MOESM2){ref-type="media"}: Table S2), the authors independently extracted important data related to study characteristics (study area, first author, year of publication, study design, population characteristics, nature of wound samples) and outcome of interests (culture positivity, nature of bacterial isolates, prevalence of bacterial isolates and resistance profile of individual isolates).

Critical appraisal of studies {#Sec10}
-----------------------------

The quality of studies was assessed using standard critical appraisal tools prepared by Joanna Briggs Institute (JBI), at University of Adelaide, Australia \[[@CR21]\]. The purpose of this appraisal is to assess the methodological quality of a study and to determine the extent to which a study has addressed the possibility of bias in its design, conduct and analysis. The JBI critical appraisal checklist for studies reporting prevalence data contains nine important questions (Q1-Q9) and primarily addresses the methodological aspects of each study. This critical appraisal was conducted to assess the internal (systematic error) and external validity of studies thereby reduces the risk of biases among individual studies. Scores of the two authors (MS and DE) in consultation with third author (TW) (in case of disagreement between the two authors' appraisal result) were taken for final decision. Studies with the number of positive responses (yes) greater than half of the number of checklists (i.e., score of five and above) were included in the systematic review and meta-analysis.

Outcome measurements {#Sec11}
--------------------

The primary outcome measures are the culture positivity of wound samples and the prevalence of bacterial isolates recovered from infected wound samples in Ethiopia. The secondary outcome measure is the antimicrobial resistance profiles of clinically relevant bacterial isolates against commonly prescribed antimicrobial agents taken from different pharmacologic categories (penicillins, cephalosporins, aminoglycosides, fluroquinolones, macrolides and sulfonamides). Subgroup analysis was also conducted based on the nature of wound sources (surgical, burn and other non-surgical wounds).

Data processing and analysis {#Sec12}
----------------------------

The extracted data were imported from Microsoft Excel to STATA software, version 15.0 for the pooled estimation of outcome measures. Sensitivity and subgroup analyses were also conducted to minimize the degree of heterogeneity. Der-Simonian-Laird's random effects model was applied for the analysis at 95% confidence level. Heterogeneity among the included studies was assessed with I^2^ statistics. Forest plots and summary tables were used to report the results. Comprehensive Meta-analysis software version-3, (Biostat, Englewood, New Jersey, USA), was employed for assessment of publication bias. The presence of publication bias was evaluated by using Egger's regression and Begg's and Mazumdar's correlation tests and presented with funnel plot. All statistical tests with *p*-values less than 0.05 (one-tailed) were considered significant \[[@CR22], [@CR23]\].

Results {#Sec13}
=======

Search results {#Sec14}
--------------

A literature search in electronic databases including PubMed, MEDLINE, EMBASE, CINAHL and Google Scholar retrieved a total of 111 studies. From which, 62 studies were found duplicate through ENDNOTE and manual tracing. The remaining studies were screened using their titles and abstracts and 21 of them did not fulfill the inclusion criteria and thus removed from further eligibility study. The full texts of 28 studies were thoroughly assessed to ensure the presence of at least the primary outcome measures in sufficient and non-ambiguous way. In this regard, 7 studies did not meet the inclusion criteria and thus removed from final inclusion. Therefore, 21 studies addressing the outcome of interest were included (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA flow diagram depicting the selection process

Results of quality assessment {#Sec15}
-----------------------------

Having fulfilled the predefined inclusion criteria, further rigorous appraisal of individual study was conducted using JBI checklist with the average quality score ranging between 6 and 9. Finally, the 21 studies were included for systematic review and meta-analysis (Table [1](#Tab1){ref-type="table"}).Table 1Quality assessment of studies using JBI's critical appraisal tools designed for cross-sectional studiesStudiesJBI's critical appraisal questionsOverall scoreIncludeQ1Q2Q3Q4Q5Q6Q7Q8Q9Abraham and Wamisho., 2009YYYYYYYUN7✓Alebachew et al., 2012NYNYNYYYY6✓Asres et al., 2017NYYYYYYYY8✓Azene et al., 2011UYYYYYYYY8✓Bitew et al., 2018UYYYYYYYY8✓Desalegn et al., 2014YYYYYYYNY8✓Dessie et al., 2016UYNYYYYYY7✓Gelaw et al., 2014UYNYYYYYY7✓Godebo et al., 2013UYYYYYYYY8✓Guta et al., 2014NYNYYYYYY7✓Hailu et al., 2016UYYYYYYNY7✓Kahsay et al., 2014YYYYYYYYY9✓Kiflie et al., 2018YYNYYYYYY8✓Lema et al., 2012NYYYYYYYY8✓Mama et al., 2014YYYYYYYYY9✓Mengesha et al., 2014YYNYYYYYY8✓Mohammed et al., 2014NYNYYYYYY7✓Mulu et al., 2006UYYYYYYYY8✓Mulu et al., 2017UYYYYYYYY8✓Sewnet et al., 2013NYNYYYYYY7✓Tekie, 2008YYYYYYYYY9✓*Y* Yes, *N* No, *U* Unclear, *Q* Question. Overall score is calculated by counting the number of Ys in each rowQ1 = Was the sample frame appropriate to address the target population? Q2 = Were study participants sampled in an appropriate way? Q3 = Was the sample size adequate? Q4 = Were the study subjects and the setting described in detail? Q5 = Was the data analysis conducted with sufficient coverage of the identified sample? Q6 = Were valid methods used for the identification of the condition? Q7 = Was the condition measured in a standard, reliable way for all participants? Q8 = Was there appropriate statistical analysis? Q9 = Was the response rate adequate, and if not, was the low response rate managed appropriately?

Study characteristics {#Sec16}
---------------------

Twenty one studies with a total of 4284 wound samples, 3012 positive cultures and 3598 bacterial isolates were included for systematic review and meta-analysis. This review included a wide range of wound samples taken from various patient sources including patients surgical wounds \[[@CR24]--[@CR32]\], patients with non-surgical and/or combined wound infections \[[@CR33]--[@CR40]\], patients with fracture \[[@CR41]\], patients with burn \[[@CR42], [@CR43]\], and patients with leprotic wound infections \[[@CR44]\]. The study period of included studies ranges from 2000 to 2018 and three of which were published before 2010 \[[@CR30], [@CR39], [@CR41]\]. Regarding the study design, all of them are laboratory based cross-sectional studies with four of them being a retrospective chart review \[[@CR33], [@CR36], [@CR39], [@CR40]\]. The number of wound samples, positive cultures and bacterial isolates ranges from 50 \[[@CR43]\] to 599 \[[@CR33]\], 21 \[[@CR43]\] to 422 \[[@CR33]\] and 47 \[[@CR43]\] to 500 \[[@CR33]\], respectively. Two studies have only recovered *S. aureus* isolates from positive cultures of wound swabs \[[@CR28], [@CR42]\]. With exception of three studies which were conducted in regional laboratories \[[@CR33], [@CR34], [@CR36]\], all the rest studies were conducted in specialized and/or teaching hospitals of Ethiopian universities. Table [2](#Tab2){ref-type="table"} has also summarized the number of clinically relevant gram-positive (*S. aureus* and CoNS) and gram-negative (*E. coli*, *P. aeruginosa*, *K. pneumoniae*, and *P. mirabilis*) bacterial isolates recovered from positive cultures of wound samples (Table [2](#Tab2){ref-type="table"}).Table 2Characteristics of included studies describing the magnitude of culture positive wound samples and microbial profiles of clinical relevant bacterial isolates in Ethiopia (2000--2018)StudiesYear of publicationStudy settingTotal patients (M/F ratio)Study characteristicsWound samplesCulture positiveNo of isolatesGram-positiveGram -negative*S. aureusCoNSE. coliP. aeruginosaK. pneumoniaeP. mirabilis*Abraham and Wamisho \[[@CR41]\]2009TASH, AA191 (158/33)Fracture in-and outpatients20019616224121716126Alebachew et al. \[[@CR42]\]2012Yekatit 12 hospital114 (58/56)Burn in-and outpatients1149511465NDNDNDNDNDAsres et al. \[[@CR24]\]2017TASH, AA197 (118/79)Postoperative in-and outpatients1971491685619248152Azene et al. \[[@CR33]\]2011Dessie regional laboratory12599 (368/231)Outpatients with any wound599422500208982921255Bitew et al. \[[@CR34]\]2018Arsho medical laboratory366 (213/153)Both in-and Patients with wound366271271110114914127Desalegn et al. \[[@CR25]\]2014Hawassa TRH194 (116/78)Post-surgical in and outpatients19413817766645182418Dessie et al. \[[@CR31]\]2016St. Paul and Yekatit 12 hosp.107 (56/51)Surgical inpatients10790104194246101Gelaw et al. \[[@CR26]\]2014UoG TH42 (27/15)Surgical inpatients142424911463109Godebo et al. \[[@CR35]\]2013JUSHNSOut/inpatients with wound3223103847314307446107Guta et al. \[[@CR27]\]2014HUTRH100 (37/63)Surgical inpatients10092177452630163212Hailu et al. \[[@CR36]\]2016Bahir Dar RHRL234 (131/103)Both in-and outpatients with wound380234234100ND33262022Kahsay et al. \[[@CR28]\]2014DMRH184 (61/123)Surgical inpatients1847318472NDNDNDNDNDKiflie et al. \[[@CR32]\]2018UoG TH107 (0/107Women with cesarean section or episiotomy107901014213201141Lema et al. \[[@CR44]\]2012Selected Hospitals, AA245 (157/88)In-and outpatients with leprosy2452222986818147247Mama et al. \[[@CR37]\]2014JUSH150 (107/43)In/outpatients with wound150131145472129111423Mengesha et al. \[[@CR29]\]2014Ayder TRH128 (98/30)Surgical inpatients1289612340186112915Mohammed et al. \[[@CR38]\]2014UoG RH137 (81/56)In/outpatients with wound137115136391788176Mulu et al. \[[@CR39]\]2006UoGTHNSIn/outpatients with wound151797951ND8ND73Mulu et al. \[[@CR40]\]2017DMRH238 (NS)In/outpatients with wound2381159070ND5613Sewnet et al. \[[@CR43]\]2013Yekatit 12 hospital50 (30/20)In/outpatients with burn case502147166ND1514Tekie \[[@CR30]\]2008TASH173 (97/76)Outpatients with surgical wound173315514117842Total428430123598*M* Male, *F* Female, *CoNS* Coagulase negative Staphylococci, *ND* Not determined, *JUSH* Jimma University Specialized Hospital, *UoGTH* University of Gondar Teaching Hospital, Hawassa University Teaching and Referral Hospital, *CS* Cross-sectional, *R* Retrospective, *TASH* Tikur Anbesa Specialized Hospital, *AA* Addis Ababa, *DMRH* Debre Markos Referral Hospital, *NS* Not specified

Besides, the antimicrobial resistance profiles of six clinical isolates (two from gram-positive and four from gram-negative bacteria) were summarized against commonly prescribed antimicrobial agents taken from various pharmacologic classes: penicillins (amoxicillin, ampicillin, amoxicillin-clavulanic acid, and methicillin), cephalosporins (ceftriaxone), fluoroquinolones (ciprofloxacin), marcrolides (erythromycin), sulfonamides (cotrimoxazole) and aminoglycosides (gentamicin). Unlike others, a study conducted by Hailu et al. utilized variable number of bacterial isolates per antimicrobial agent \[[@CR36]\]. Antimicrobial susceptibility testing of gram-negative isolates was conducted against erythromycin in two studies \[[@CR29], [@CR33]\] though not found suitable for meta-analysis (Table [3](#Tab3){ref-type="table"}).Table 3Antimicrobial resistance patterns of clinically relevant bacterial isolates from wound infection in EthiopiaTypes of BacteriaStudiesNumber of isolatesNumber of isolates resistant toAMOAMCAMPCIPCROSXTERYGENMET*S. aureus*Abraham and Wamisho249620426235Alebachew et al66--22----23--9--51Asres et al.56--9--7--19976Azene et al208165----1837140722622Bitew et al110------7--30702--Kiflie et al4228--30--1526----22Desalegn et al6620632654372926--Dessie et al19------3--443--Godebo et al73----67101544581257Guta et al4545------16----9--Hailu et alNDA------5(67)--16 (94)30 (96)--20 (95)Kahsay et al7313--13----1--936Lema et al68458586--2320550Mama et al47----4527372--Mengesha et al40372036--36--9434Mohammed et al3934----881524730Mulu et al., 200651----28----18------*CoNS*Abraham and Wamisho121--411--12Asres et al.19--15--5--141112Kiflie et al1311--11--58----Desalegn et al6--3636333Dessie et al4------4--333Godebo et al14----902500Guta et al264------13----13Lema et al186--121--993Mama et al21----1956384Mengesha et al18161414--13--99Mohammed et al1613----38783*E. coli*Abraham and Wamisho17847125--2Asres et al.242014--5--15--7Azene et al8270----2155554312Bitew et al49--353551022--5Kiflie et al2014--1641210--7Desalegn et al45--2145181827--21Dessie et al24--17231620----13Godebo et al30----231206--0Guta et al3020------10----0Hailu et alNDA--24 (33)31 (33)15 (33)6 (24)23 (30)--18 (33)Lema et al141079----9----Mama et al29----29101816--15Mengesha et al646614--2--Mohammed et al8----6314--1Mulu et al., 20068----7----5----*P. aeruginosa*Abraham and Wamisho161313140511--2Asres et al.887--1--7--2Azene et al9276----44771837Bitew et al14--14141119--1Desalegn et al18--181801812--9Dessie et al6--6625----0Godebo et al74----724765--8Guta et al1616------8----8Hailu et alNDA------5 (26)--3 (9)--7 (23)Lema et al7676----7--1Mama et al11----11--78--2Mengesha et al11111111911--3--Mohammed et al8------33----3Tekie8------647--3*K. pneumoniae*Abraham and Wamisho128412033--3Asres et al.151412--41313--9Azene et al1212--------8--0Bitew et al12--1212275--2Kiflie et al1414--14289--3Desalegn et al24--1221152121--24Dessie et al10--101029----4Godebo et al46----32131330--13Guta et al3225------9----12Hailu et alNDA--10 (20)15 (20)4 (20)2 (18)8 (20)--11 (18)Mama et al14----1451012--9Mengesha et al292919261125--138Mohammed et al17----1610911--5*P. mirabilis*Abraham and Wamisho6211003--0Azene et al5548----93545515Bitew et al7--45255--2Desalegn et al18--918063--6Godebo et al107----778881--35Guta et al1211------8----6Hailu et alNDA--12 (22)17 (22)5 (22)8 (18)7 (17)--5 (22)Lema et al472420314--21--4Mama et al23----214159--6Mengesha et al1515713711--93Mohammed et al6----6215--2\-\--, Not tested, *NDA* Number of isolates is different among antimicrobial agents tested as indicated in parenthesis of the corresponding rows, *AMO* Amoxicillin, *AMP* Ampicillin, *AMC* Amoxicillin-clavulanic acid, *SXT* Cotrimoxazole, *CRO* Ceftriaxone, *CIP* Ciprofloxacin, *GEN* Gentamicin, *ERY* Erythromycin

Outcome measures {#Sec17}
----------------

### Primary outcome measures: culture positivity and microbial epidemiology {#Sec18}

In this meta-analysis, a total of 3012 positive bacterial cultures obtained from 4284 wound samples were included. The pooled prevalence of culture positive cases from all wound samples was found to be 70.0% (95% CI: 61, 79%) (Fig. [2](#Fig2){ref-type="fig"}). Subgroup analysis was conducted to determine whether there is a potential difference of culture positivity among wound sources. Based on this, the prevalence of culture positive samples in non-specific non-surgical simple or compound wounds was estimated about 77% (95% CI: 67, 86%). Likewise, the prevalence of cultures with bacterial growth among burn wounds was estimated 75% (95% CI: 69, 81%). In surgical wounds, a relatively lower culture positivity rate was obtained with a pooled estimate being 63% (95% CI: 45, 82%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Forest plot depicting culture positivity among wound sample in EthiopiaFig. 3Forest plot showing subgroup analysis of culture positivity based on wound sources

Gram-positive cocci were a predominant isolates recovered. The pooled prevalence of *S. aureus* was 36% (95% CI: 29, 42%) (Fig. [4](#Fig4){ref-type="fig"}). The prevalence of CoNS isolates from wound samples was estimated to be 8% (95% CI: 6, 10%) (Fig. [5](#Fig5){ref-type="fig"}). With regard to gram-negative aerobic bacilli, the pooled estimates of *E. coli* isolates from all isolates of wound samples was found to be 13% (95% CI: 10, 16%) (Fig. [6](#Fig6){ref-type="fig"}) followed by *P. aeruginosa*, 9% (95% CI: 6, 12%) (Fig. [7](#Fig7){ref-type="fig"}), *K. pneumoniae*, 9% (95% CI: 6, 11%) (Fig. [8](#Fig8){ref-type="fig"}) and *P. mirabilis*, 8% (95% CI: 5, 11%) (Fig. [9](#Fig9){ref-type="fig"}).Fig. 4Prevalence of *S. aureus* in wound samplesFig. 5Pooled estimate of CoNS in wound samples in EthiopiaFig. 6Pooled estimates of *E. coli* in wound samplesFig. 7Forest plot depicting the pooled prevalence of *P. aeruginosa* in wound samplesFig. 8Pooled estimates of *K. pneumoniae* in wound samplesFig. 9Pooled estimate of *P. mirabilis*

### Secondary outcome measures: antimicrobial resistance patterns {#Sec19}

Among *S. aureus* isolates, the prevalence of Methicillin resistant *S. aureus* (MRSA) strains was found to be 49% (95% CI: 31, 68%). The combination of amoxicillin with *β*-lactamase inhibitor clavulanic acid (Coamox-clav) reduced the amoxicillin resistance by 42% (*P* = 27%; 95% CI: 16, 38%). Besides, the pooled estimates of amoxicillin and ampicillin resistance among CoNS isolates were 62% (95% CI: 34, 90%) and 72% (95% CI: 57, 87%), respectively. Among all antimicrobial agents tested, *S. aureus* exhibited relatively lower estimates of resistance against ciprofloxacin, 12% (95% CI: 8, 16%) and gentamicin, 13% (95% CI: 8, 18%). Likewise, ciprofloxacin had the least resistant isolates (*P* = 13%; 95% CI: 4, 23%) followed by gentamicin (*P* = 33%; 95% CI: 17, 50) for CoNS. The 3rd generation cephalosporin ceftriaxone resistance was observed among gram-positive isolates with estimates being 36% (95% CI: 17, 55%) and 37% (95% CI: 19, 54) for *S. aureus* and CoNS, respectively (Table [4](#Tab4){ref-type="table"}).Table 4Pooled estimates of antimicrobial resistance among Gram-positive bacteria obtained from wound samples in EthiopiaAntimicrobial agentsPooled estimates of resistant isolates (Proportion)*S. aureusCoNS*Pooled ES (95% CI)I^2^ (%)Pooled ES (95% CI)I^2^ (%)AMO0.69 (0.50, 0.87)97.640.62 (0.34, 0.90)93.05AMC0.27 (0.16, 0.38)81.35NA--AMP0.76 (0.60, 0.92)97.170.72 (0.57,0.87)70.85CIP0.12 (0.08, 0.16)72.390.13 (0.04, 0.23)65.46CRO0.36 (0.17, 0.55)97.230.37 (0.19, 0.54)81.58SXT0.35 (0.20, 0.49)97.640.49 (0.31, 0.66)75.21ERY0.34 (0.22, 0.46)94.690.40 (0.20, 0.40)90.05GEN0.13 (0.08, 0.18)82.900.33 (0.17, 0.50)88.16MET0.49 (0.31, 0.68)94.50NA--*AMO* Amoxicillin, *AMP* Ampicillin, *AMC* Amoxicillin-clavulanic acid, *SXT* Cotrimoxazole, *CRO* Ceftriaxone, *CIP* Ciprofloxacin, *GEN* Gentamicin, *MET* Methicillin, *ERY* Erythromycin, *NA* Not analyzed: CoNS, Coagulase negative Staphylococci

Regarding the AMR profiles of gram-negative pathogens, *E. coli* isolates exhibited the highest point estimate of resistance against ampicillin (*P* = 84%; 95% CI: 76, 91%) followed by amoxicillin (*P* = 73%; 95% CI: 63, 83%). Gentamicin and ciprofloxacin showed relatively lower estimates of resistance with pooled prevalence being 24% (95% CI: 16, 33%) and 27% (95% CI: 16, 37%), respectively. Amoxicillin-clavulanic acid combination reduced the amoxicillin resistance of *E. coli* by 16% (*P* = 57%; 95% CI: 44, 70%). Nearly half (*P* = 45%; 31, 60%) and more than half (*P* = 53%; 95% CI: 43, 64%) of *E. coli* isolates were found resistant to ceftriaxone and cotrimoxazole, respectively in wound samples in Ethiopia (Table [5](#Tab5){ref-type="table"}).Table 5Pooled estimates of antimicrobial resistance among Gram-negative bacterial isolates obtained from wound samples in EthiopiaAntimicrobialsPooled estimates of resistant isolates (Proportion)*E. coliP. aeruginosaK. pneumoniaeP. mirabilis*ES (95% CI)I^2^ (%)ES (95% CI)I^2^ (%)ES (95% CI)I^2^ (%)ES (95% CI)I^2^ (%)AMO0.73 (0.63, 0.83)55.700.87 (0.82, 0.92)0.000.90 (0.83, 0.97)43.970.75 (0.57, 0.93)86.81*AMC*0.57 (0.44, 0.70)74.510.77 (0.63, 0.91)63.670.67 (0.51, 0.83)78.010.45 (0.36, 0.54)19.01AMP0.84 (0.76, 0.91)75.080.95 (0.92, 0.99)0.000.88 (0.83, 0.93)24.270.78 (0.70, 0.85)39.67CIP0.27 (0.16, 0.37)86.990.16 (0.09, 0.24)87.630.29 (0.15, 0.42)85.500.12 (0.06, 0.19)73.68CRO0.45 (0.31, 0,60)89.810.58 (0.35, 0.82)95.860.57 (0.39, 0.75)92.320.43 (0.24, 0.63)94.04SXT0.53 (0.43, 0.64)75.910.76 (0.68, 0.85)51.820.64 (0.51, 0.77)76.580.56 (0.39, 0.72)88.19GEN0.24 (0.16, 0.33)93.090.18 (0.11, 0.26)66.470.37 (0.22, 0.52)89.660.21 (0.12, 0.30)74.31*AMO* Amoxicillin, *AMP* Ampicillin, *AMC* Amoxicillin-clavulanic acid, *SXT* Cotrimoxazole, *CRO* Ceftriaxone, *CIP* Ciprofloxacin, *GEN* Gentamicin

Though it has become clinical concerning, the difficult to treat gram-negative bacteria *P. aeruginosa* showed the lowest pooled estimates of resistance against ciprofloxacin (*P* = 16%; 95% CI: 9, 24%, I^2^ = 87.63). Only 10% reduction in overall resistance was observed in amoxicillin-clavulanate (*P* = 77; 95% CI: 63, 91%) compared to amoxicillin alone (*P* = 87%; 95% CI: 82, 92%) in *P. aeruginosa* isolates.. More than half of *P. aeruginosa* isolates (*P* = 58%; 95% CI: 35, 82%) developed resistance to ceftriaxone. Moreover, around three-fourths of these isolates (*P* = 76%; 95% CI: 68, 85%) were found resistant to cotrimoxazole (Table [5](#Tab5){ref-type="table"}).

The AMR profiles of the two more gram-negative aerobic bacilli (*K. pneumoniae* and *P. mirabilis*) were also tested against seven antimicrobial agents. The antimicrobials with highest estimates of resistance were found to be amoxicillin and ampicillin in both bacterial isolates. Ciprofloxacin followed by gentamicin were antimicrobials having lower point estimates of resistance in both types of isolates. More than half of *K. pneumoniae* isolates exhibited ceftriaxone resistance (*P* = 57%; 95% CI: 39, 75%) (Table [5](#Tab5){ref-type="table"}).

### Publication bias {#Sec20}

Funnel plots of standard error with log of the prevalence of positive bacterial cultures revealed that there is some evidence of publication bias (Begg's and Mazumdar's test, *p*-value =0.0067; Egger's test, *p*-value = 0.048) (Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Funnel plot showing publication bias of included studies

Discussion {#Sec21}
==========

In this systematic review and meta-analysis, more than two-thirds of wound samples (70%) were found culture positive. The subgroup analysis has also indicated higher culture positivity of burn and other non-surgical wounds compared to surgical wounds regardless of prophylactic antibiotic status. In concordant with this, a five year study conducted by Agnihotri et al reported high culture positivity (96%) from burn wound infections \[[@CR6]\]. Besides, a summary of wound infection in orthopedics revealed that the overall culture positivity rate was estimated to be 53% \[[@CR45]\]. The lower culture positivity of surgical wounds, as observed in subgroup analysis, might be due to the nature of surgical care (i.e. irrigation, debridement and use of prophylactic antibiotics in some cases). The most common bacterial isolate recovered from wound infection was *S. aureus* with pooled estimate being 36% which is by far higher than the prevalence of CoNS, *E. coli*, *P. aeruginosa*, *K. pneumoniae* and other gram-negative aerobic bacilli. This is further supported by several published studies which reported that gram-positive aerobic cocci, particularly, *Staphylococci*, have been the primary cause of wound infections \[[@CR3]--[@CR5], [@CR7]--[@CR9], [@CR46]--[@CR50]\]. More specifically, *S. aureus* has been a single most common pathogen isolated from several wound samples \[[@CR46]--[@CR49], [@CR51]\]. With regard to gram-negative pathogens, the highly prevailing clinically relevant bacterial isolates were aerobic bacilli under Enterobacteriaceae including *E. coli*, *P. aeruginosa*, *K. pneumoniae*, and *P. mirabilis*. This finding is in trajectory with review of recent literature in different settings \[[@CR14], [@CR45], [@CR48], [@CR52]\].

Though it seems controversial, many studies indicated that the two highly prevalent bacterial isolates recovered from chronic wound infections were *S. aureus* and *P. aeruginosa* \[[@CR3], [@CR12], [@CR15], [@CR49], [@CR51], [@CR53], [@CR54]\]. Nevertheless, a review report conducted by Macedo and Santos on burn wound infections showed that *S. aureus* was the most prevalent in the first week of wound infection with an overall prevalence of about 28.4%. It was, however, surpassed by *P. aeruginosa* from the third week onwards \[[@CR55]\]. On the top of these, *S. aureus* and *P. aeruginosa* are opportunistic pathogenic bacteria and are widely known to cause chronic biofilm-based wound infections \[[@CR51]\]. These pathogens are capable of making a strong biofilm that maintains the chronic infection which impairs wound healing \[[@CR3], [@CR53]\]. To this end, a meta-analysis of published data revealed that about 78% of non-healing chronic wounds harbor biofilms, with prevalence rates varying between 60 and 100% \[[@CR12]\].

The overall prevalence of MRSA strains was found to be 49% indicating one in every two *S. aureus* isolates were characterized as MRSA strains. This is a clear direction of how high the healthcare settings become a reservoir of resistant strains like MRSA. Likewise, a summary of wound infections in orthopedics indicated that *S. aureus* constituted about 34% of all isolates and 48% of this isolate were reported to be MRSA \[[@CR45]\]. Conditions such as hospitalization, prophylactic use of antimicrobials in surgical procedures and use of broad spectrum antimicrobials predispose patients for such resistant strains \[[@CR3]\]. The rapid development and spread of MRSA clones across the globe often results in such hospital outbreaks \[[@CR56], [@CR57]\].

Due to β- lactamase producing capability and modification of penicillin binding proteins*, S. aureus* has developed resistance to majority of β-lactam antibiotics (mainly penicillins and cephalosporins). As the analysis tried to address, the third generation cephalosporin ceftriaxone resistance was estimated to be 36%. Though it is less pathogenic than *S. aureus*, CoNS had also developed closer estimates of resistance in these antibiotics. Most notably, the steady erosion of the effectiveness of β-lactam antibiotics for treatment of *S. aureus* infection is due to the fact that it's extraordinary adaptability in developing resistance with several mechanisms \[[@CR10], [@CR56], [@CR57]\]. Gram-positive cocci particularly *Staphylococci* such as *S. aureus* produce β-lactamase enzymes which in turn degrade the β-lactam ring of majority of β-lactam antibiotics (penicillins, cephalosporins, carbapenems and monobactams) and make these drugs devoid of any antibacterial activity. Though they have a wide range of bacterial coverage, the β-lactamase sensitivity of broad (ampicillin and amoxicillin) and extended spectrum (antipseudomonal) penicillins are no longer effective for β-lactamase producing *Staphylococci* such as *S. aureus* \[[@CR6], [@CR14], [@CR56], [@CR58]\]. To this end, the use of combination of β-lactamase enzyme inhibitors (e.g. clavulanic acid, sulbactam, tazobactam) with these sensitive β-lactam antibiotics has been somehow a notable strategy in combating resistance against strains constitutionally producing these enzymes. In this study, combination of amoxicillin with clavulanic acid (Coamox-clav) reduced the pooled estimates of amoxicillin resistance from 69 to 27% clearly indicating the involvement of these enzymes in resistance development. This finding is in trajectory with a 5-year study conducted by Agnihotri et al. in which *S. aureus* showed high estimate of resistance (about 75%) to standard β-lactam antibiotics whereas coamox-clav resistance was reduced to 23.5% \[[@CR6]\].

Moreover, *S. aureus* has also developed resistant to β-lactamase resistant penicillins (methicillin, naficillin, oxacillin, cloxacillin and diclocoxacillin) with apparently different mechanism. From experience, resistant to these agents was historically treated as MRSA since the first agent in this class of penicillins is methicillin \[[@CR59]--[@CR61]\]. *S. aureus* acquires resistance genes which encode a modified form of penicillin binding proteins (PBP). In MRSA, the horizontally acquired *mecA* gene encodes PBP2A. PBP2 is the only bifunctional PBP in *S. aureus*. In MRSA strains, the essential function of PBP2 may be replaced by PBP2A which functions as a surrogate transpeptidase. Since almost all β-lactams have little or no affinity to this protein, cross resistance occurs regardless of β-lactamase stability status \[[@CR57], [@CR60]\]. This is a likely justification why more-than one-thirds of *S. aureus* strains were found resistant to ceftriaxone. Apart from this, macrolides (erythromycin) and sulfa drugs (cotrimoxazole) resistance was observed in about one-thirds of *S. aureus* strains. Generally, this study showed that more than 10% of *S. aureus* isolates were also resistance to ciprofloxacin and gentamicin. CoNS had also showed higher gentamicin resistance than *S. aureus*.

Observing the AMR profile of gram-negative bacteria, a high estimate of resistance was observed in β-lactam antibiotics. All gram-negative bacilli have developed clinically significant resistant against broad spectrum penicillins (amoxicillin and ampicillin). The combination of β-lactamase inhibitor clavulanic acid with amoxicillin did not show an appreciable reduction. The Coamox-clav resistance in *P. aeruginosa* was about 77%. Likewise, more than 50% of *P. aeruginosa* and *K. pneumoniae* isolates had developed resistance to the third generation cephalosporin ceftriaxone. From sulfa drug combination, cotrimoxazole resistance was observed in more than half of all isolates in each gram-negative bacterium with the highest resistance estimate (76%) observed in *P. aeruginosa*. Even if the degree of susceptibility varies across strains, relatively lower estimates of resistance were observed in ciprofloxacin and gentamicin making these agents relatively effective for treatment of wound infections.

In this regard, a plasmid encoded extended-spectrum β-lactamases (ESBLs) production has been alarmingly increasing in gram-negative bacteria particularly in *Enterobacteriaceae* \[[@CR62]--[@CR64]\]. A study indicated that among *K. pneumoniae* and *E. coli* isolated from wound samples, around 11% produced ESBL (12.2 and 10.3% for *K. pneumoniae* and *E. coli*, respectively) \[[@CR62]\]. ESBLs have the ability to hydrolyze extended spectrum β-lactams including third generation cephalosporins (e.g. ceftriaxone, ceftazidime and cefotaxime) and the monobactams (aztreonam). Carbapenems have been the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported \[[@CR63], [@CR65]--[@CR67]\].

The difficult to treat gram-negative bacteria *P. aeruginosa* has naturally known to develop resistance by its outer membrane (porine channels) permeability problems coupled to adaptive mechanisms such as efflux pumps and can readily achieve clinical resistance. Almost all penicillins, except the fourth generation series (antipseudomonal agents such as ticarcillin and piperacillin), are not clinically effective at all for the treatment of *Pseudomonas* infections.. Likewise, majority of the third generation cephalosporins and all of the prior generations are no longer effective since they are not able to penetrate the porine channels of this bacterium though other resistance mechanisms should also be considered. Generally, this bacterium is highly notorious to develop resistance to multiple antibiotics and has joined the ranks of 'superbugs' due to its enormous capacity to engender resistance \[[@CR48], [@CR68]--[@CR73]\].

Historically, the classes of antibiotics used in the treatment of wound infections include the β -lactams and aminoglycosides \[[@CR47]\]. At present, guidelines have indicated that antibiotics prescribing practice primarily relies on expert opinion not on evidence based medicine. This has now created difficulties in interpreting and implementing it in clinical settings \[[@CR15]\]. Besides, inappropriate use of antibiotics for surgical prophylaxis increases both the cost and the selective pressure favoring the emergence of resistant strains. Published reports indicated that, from about 30--50% of antibiotics being used for surgical prophylaxis, between 30 and 90% of it is potentially inappropriate \[[@CR16], [@CR74], [@CR75]\]. The meta-analysis has vividly indicated that wound is contaminated with multiple microorganisms (poly-microbial infection) and hence antibiotic treatment should be tailored according to the microbial profiles. Particularly, *S. aureus* and *P. aeruginosa* are among the pathogen of interest and have several resistance mechanisms making the treatment challenging. In general, the most common drugs used to treat *S. aureus* infections include amoxicillin/clavulanate, ampicillin/sulbactam, and cloxacillin whereas MRSA strains are better treated with levofloxacin, vancomycin, linezolid and tigecycline. In the presence of co-infections related to *S. aureus* and *P. aeruginosa*, piperacillin/tazobactam, carbapenems and ciprofloxacin may represent the first choice for treatment of wound infections \[[@CR53]\].

Conclusion {#Sec22}
==========

Generally, the wound culture positivity was very high indicating the likelihood of poly-microbial load. Surgical wounds had relatively lower culture positivity than non-surgical counterparts though the role of prior local wound care following surgery is yet to be investigated. *Staphylococci* have been the predominant gram-positive cocci in wound infection with *S. aureus* being by far the most prevalent isolate. This finding alarms the high load of MRSA strains in hospital settings as well. Gram-negative aerobic bacilli under *Enterobacteriaceae* are also commonly isolated pathogens in wound infections. Though it is expected in *S. aureus* and *P. aeruginosa*, all isolates exhibited highest estimates of resistance against β-lactam antibiotics. Most notably, resistance to the 3rd generation cephalosporin ceftriaxone was observed in more than 40% of all gram-negative isolates (more than half in *K. pneumoniae* and *P. aeruginosa*). Though more than 10% of resistance was reported in all isolates, ciprofloxacin and gentamicin were relatively good in treating wound infections with poly-microbial etiology. Hence, considering microbial epidemiology and AMR patterns, treatment should be tailored for addressing poly-microbial etiology thereby effectively manage wound infection and its complication as well as preserve antimicrobials and contain AMR.

Limitation of the study {#Sec23}
-----------------------

Even if the study has extensively included all relevant data regarding wound infection, it was not without limitations. There was no clear demarcation of wound samples in inpatient and outpatient settings. Besides, there was no documented history of prophylactic use of antibiotics in individual studies though we conducted subgroup analyses to reduce culture positivity/negativity errors in surgical patients. The antimicrobial susceptibility testing was a little bit different across studies. Therefore, this meta-analysis should be seen in the context of such limitations.
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Additional file 1:**Table S1**. Completed PRISMA checklist: The checklist highlights the important components addressed while conducting systematic review and meta-analysis from observational studies (DOC 66 kb) Additional file 2:**Table S2.** Data abstraction format with crude data: The table presented the ways of data collection (study characteristics and outcome measures) in Microsoft excel format. (XLSX 38 kb)
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